Author

Xiaomin Wang

Institution: Anyang Tumor Hospital

Observed institutions: Henan University of Science and Technology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Medical University Cancer Institute and Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, Anyang Tumor Hospital

ORCID: 0000-0003-0336-5526

Observed ORCID: 0000-0003-0336-5526

OpenAlex ID: A5023044172

Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial

2025 · Yupei Yuan, Shihong Luo, et al. · Radiation Oncology · 5

Neoadjuvant immunochemotherapy for resectable esophageal cancer: A study on efficacy and safety

2025 · Xiaomin Wang, Bingxu Li, et al. · Biomolecules and Biomedicine · 4

Effects of N6-Methyladenosine Regulators on LAG3 and Immune Infiltrates in Lung Adenocarcinoma

2022 · Nengchao Wang, Yue Xu, et al. · Disease Markers · 3

Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III Trial

2026 · Shengnan Hao, Xiaomin Wang, et al. · Future Oncology · 2

Efficacy and safety of the combination of tisleizumab with chemoradiotherapy in oligorecurrence esophageal squamous cell carcinoma: A prospective phase II study.

2024 · Ziyu Zheng, Xiaomin Wang, et al. · Journal of Clinical Oncology · 2

A machine learning approach for radiation pneumonitis prediction in elderly esophageal cancer patients by integrating baseline computed tomography radiomics, dosiomics, and clinical characteristics

2025 · Zhunhao Zheng, Junqiang Chen, et al. · Physics and Imaging in Radiation Oncology · 1

Works count: 6

Citation count: 17

H-index: 3

I10-index: